1. Opko Health. Opko health announces update on phase III clinical trial of bevasiranib.
http://investor.opko.com/releasedetail.cfm?ReleaseID=369294
(Opko Health, 6 March 2009).
2. Alnylam Pharmaceuticals. Alnylam and Cubist announce complete data from phase II study of ALN-RSV01 in lung transplants patients naturally infected with respiratory syncytial virus
http://phx.corporate-ir.net/preview/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1308924&highlight=
(Alnylam Pharmaceuticals, 20 July 2009).
3. Davis, M.E. et al. Nature 464, 1067–1070 (2010).
4. Couzin-Frankel, J. Science 330, 1163 (2010).
5. Macron, D. Pfizer to shut down oligo therapeutics unit as part of restructuring. Gene Silencing News
http://www.genomeweb.com/rnai/pfizer-shut-down-oligo-therapeutics-unit-part-restructuring
(3 February 2011).